Overall, 7.7% of all tumors possessed any PBAF complex mutation; incidence among malignancies included in the pan-cancer TCGA cohort was highest in ccRCC (KIRC) particularly for PBRM1 mutations, followed by melanoma (SKCM), cholangiocarcinoma (CHOL), stomach (STAD), uterine (UCEC), and bladder (BLCA) cancers (Fig. 1a, b). This evidence concerns the gene PBRM1 and bladder transitional cell carcinoma.